Literature DB >> 9212121

Midazolam premedication delays recovery after propofol without modifying involuntary movements.

J C Bevan1, G R Veall, A J Macnab, C R Ries, C Marsland.   

Abstract

Midazolam has GABAergic effects in children that may modify propofol-induced involuntary movements, yet delay recovery. In a double-blind, randomized study, 24 children (2-7 yr of age, ASA physical status I or II) undergoing short surgical procedures received midazolam 0.5 mg/kg (Group M) or placebo (Group P) per os 20-30 min before propofol anesthesia (5 mg/kg intravenously followed by an infusion). Blind observers scored sedation and anxiety levels (scale 1-4) before premedication, at separation from parents, and at induction of anesthesia. Induction and emergence were videotaped, and body movements were recorded. During recovery, times to eye opening and maximum Steward (SS = 6) and Vancouver Sedative Recovery (VSRS = 22) scores were noted. Parents were questioned about side effects that may have occurred during the following week. Both groups were similar in age, sex, weight, timing of premedication, propofol dose, and duration of surgery. The incidence of involuntary movements did not differ between groups but was higher at induction (79%) than on emergence (25%) (P < 0.05). Anxiety and sedation scores were similar in Group P and Group M, but recovery took longer after midazolam, with eye opening (mean +/- SD) 24 +/- 7 vs 43 +/- 18 min, maximum SS (median and range) 27 (13-37) vs 55 (24-138) min, and maximum VSRS 51 (30-100) vs 80 (50-130) min. Children returned to normal activity in 1 (0-5) day, and none exhibited neurological complications. We conclude that an oral premedicant dose of midazolam prolongs recovery from anesthesia in children without affecting dystonic movements after propofol.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212121     DOI: 10.1097/00000539-199707000-00009

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.

Authors:  Lenneke Schrier; Rob Zuiker; Frans W H M Merkus; Erica S Klaassen; Zheng Guan; Bert Tuk; Joop M A van Gerven; Ronald van der Geest; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2016-12-20       Impact factor: 4.335

Review 2.  General anesthesia, sleep, and coma.

Authors:  Emery N Brown; Ralph Lydic; Nicholas D Schiff
Journal:  N Engl J Med       Date:  2010-12-30       Impact factor: 91.245

3.  A case of propofol-induced delayed-onset refractory myoclonic seizures.

Authors:  Hyung Won Jeon; Ji Hye Kang; Hyun Sook Kim; Hee Young Jo; Sang-Ho Kim
Journal:  J Clin Neurol       Date:  2007-09-20       Impact factor: 3.077

4.  Premedication with midazolam in intellectually disabled dental patients: intramuscular or oral administration? A retrospective study.

Authors:  H Hanamoto; A Boku; M Sugimura; A Oyamaguchi; M Inoue; H Niwa
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-07-01

Review 5.  Characteristics of electroencephalogram signatures in sedated patients induced by various anesthetic agents.

Authors:  Byung-Moon Choi
Journal:  J Dent Anesth Pain Med       Date:  2017-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.